📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A new oncolytic Vacciniavirus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery. (2020)

First Author: Ahmed J

Attributed to: Development of an effective therapeutic regime for preventing cancer recurrence after surgery using a novel viro-immunotherapeutic agent funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/jitc-2019-000415

PubMed Identifier: 32217766

Publication URI: http://europepmc.org/abstract/MED/32217766

Type: Journal Article/Review

Volume: 8

Parent Publication: Journal for immunotherapy of cancer

Issue: 1

ISSN: 2051-1426